Researcher Profile

Researcher Profile

Monika Joshi, MD, MRCP

Monika Joshi, MD, MRCP

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Disease Teams:
Genitourinary Cancer
muj14@psu.edu

Research Interests

Dr. Monika Joshi’s research focus is in the field of genitourinary tumors, particularly in the field of immunotherapy and targeted therapy.

  • Therapeutics
  • Neoplasms
  • Carcinoma
  • Survival
  • Non-Small Cell Lung Carcinoma
  • Immunotherapy
  • Renal Cell Carcinoma
  • Drug Therapy
  • Urinary Bladder Neoplasms
  • Prostatic Neoplasms
  • Smoking
  • Smokers

Clinical Trials

A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Various Regimens of Erdafitinib in Subjects with Metastatic or Locally Advanced Urothelial Cancer
APG-115 - A Phase Ib/II Study of APG-115 in Combination with Pembrolizumab in Patients with Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With or Without Atezoluzumab in Localized Muscle Invasive Bladder Cancer
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 Study of Bladder-SparIng ChemoradiatioN with CIPosItive bladdeR cancEr (INSPIRE)EA8185
Computer-Aided Diagnosis of Cancer in Urinary Tract on Multi-Detector Row CT Urography
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Renal Cell Cancer (PDIGREE)
A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence
A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features RTOG 3506, STEEL
Evaluation of Biomarkers in Bladder Cancer Patients in the Neoadjuvant Setting
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
COVID-19 Vaccination in Cancer Patients COVID-19 Vaccination Behavior and Outcomes in Cancer Patients
One Time Tissue and Blood Collection from Patients with Lung Cancer at Risk for Developing Lung Cancer
Tissue and Blood Collection from Patients with Suspected Lung Cancer

Recent Publications

2021

Khaki, AR, Li, A, Diamantopoulos, LN, Miller, NJ, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Koshkin, V, Park, J, Alva, A, Bilen, MA, Stewart, T, Santos, V, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Lythgoe, MP, Pinato, DJ, Murgic, J, Fröbe, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Alonso Buznego, L, Duran, I, Moses, M, Barata, P, Galsky, MD, Sonpavde, G, Yu, EY, Shankaran, V, Lyman, GH & Grivas, P 2021, 'A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors', European Urology Oncology, vol. 4, no. 3, pp. 464-472. https://doi.org/10.1016/j.euo.2020.12.006
Joshi, M, Holder, SL, Zhu, J, Zheng, H, Komanduri, S, Warrick, J, Yasin, H, Gajre, R, Jia, B, Drabick, JJ, DeGraff, DJ & Zakharia, Y 2021, 'Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study', European Urology Focus. https://doi.org/10.1016/j.euf.2021.03.005
Nesterova, D, Zhu, J, Kramer, C, Vasekar, M, Truica, C, Joshi, A, Hayes, M, Kessler, J, Saunders, EFH, Drabick, J & Joshi, M 2021, 'Group-led creative writing and behavioural health in cancer: a randomised clinical trial', BMJ Supportive and Palliative Care. https://doi.org/10.1136/bmjspcare-2020-002463
Esagian, SM, Khaki, AR, Diamantopoulos, LN, Carril-Ajuria, L, Castellano, D, De Kouchkovsky, I, Park, JJ, Alva, A, Bilen, MA, Stewart, TF, McKay, RR, Santos, VS, Agarwal, N, Jain, J, Zakharia, Y, Morales-Barrera, R, Devitt, ME, Nelson, A, Hoimes, CJ, Shreck, E, Gartrell, BA, Sankin, A, Tripathi, A, Zakopoulou, R, Bamias, A, Rodriguez-Vida, A, Drakaki, A, Liu, S, Kumar, V, Lythgoe, MP, Pinato, DJ, Murgic, J, Fröbe, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Alonso Buznego, L, Duran, I, Moses, M, Barata, P, Galsky, MD, Sonpavde, G, Yu, EY, Msaouel, P, Koshkin, VS & Grivas, P 2021, 'Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes', BJU International, vol. 128, no. 2, pp. 196-205. https://doi.org/10.1111/bju.15324
Hadjiiski, L, Joshi, M, Alva, A, Chan, HP, Cohan, RH, Caoili, EM, Kirova-Nedyalkova, G, Davenport, MS, Shankar, PR, Francis, IR, Cha, KH, Samala, RK, Palmbos, PL & Weizer, AZ 2021, Multi-institutional observer performance study for bladder cancer treatment response assessment in CT urography with and without computerized decision support. in MA Mazurowski & K Drukker (eds), Medical Imaging 2021: Computer-Aided Diagnosis., 115971K, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, vol. 11597, SPIE, Medical Imaging 2021: Computer-Aided Diagnosis, Virtual, Online, United States, 2/15/21. https://doi.org/10.1117/12.2582331
KEYNOTE-361 Investigators 2021, 'Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial', The Lancet Oncology, vol. 22, no. 7, pp. 931-945. https://doi.org/10.1016/S1470-2045(21)00152-2

2020

The COVID-19 and Cancer Consortium 2020, 'A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance', Cancer Cell, vol. 38, no. 6, pp. 761-766. https://doi.org/10.1016/j.ccell.2020.10.022
Joshi, M, Grivas, P, Mortazavi, A, Monk, P, Clinton, SK, Sue-Ann Woo, M, Holder, SL, Drabick, JJ & Yin, M 2020, 'Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer', Cancer medicine, vol. 9, no. 24, pp. 9365-9372. https://doi.org/10.1002/cam4.3552
COVID-19 and Cancer Consortium 2020, 'Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study', The Lancet, vol. 395, no. 10241, pp. 1907-1918. https://doi.org/10.1016/S0140-6736(20)31187-9
Necchi, A, Madison, R, Pal, SK, Ross, JS, Agarwal, N, Sonpavde, G, Joshi, M, Yin, M, Miller, VA, Grivas, P, Chung, JH & Ali, SM 2020, 'Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma', European Urology Focus. https://doi.org/10.1016/j.euf.2020.08.001
Miller, NJ, Khaki, AR, Diamantopoulos, LN, Bilen, MA, Santos, V, Agarwal, N, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Lyman, GH & Grivas, P 2020, 'Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study', The Journal of Urology, vol. 204, no. 1, pp. 63-70. https://doi.org/10.1097/JU.0000000000000761
Khaki, AR, Li, A, Diamantopoulos, LN, Bilen, MA, Santos, V, Esther, J, Morales-Barrera, R, Devitt, M, Nelson, A, Hoimes, CJ, Shreck, E, Assi, H, Gartrell, BA, Sankin, A, Rodriguez-Vida, A, Lythgoe, M, Pinato, DJ, Drakaki, A, Joshi, M, Isaacsson Velho, P, Hahn, N, Liu, S, Alonso Buznego, L, Duran, I, Moses, M, Jain, J, Murgic, J, Baratam, P, Barata, P, Tripathi, A, Zakharia, Y, Galsky, MD, Sonpavde, G, Yu, EY, Shankaran, V, Lyman, GH & Grivas, P 2020, 'Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors', Cancer, vol. 126, no. 6, pp. 1208-1216. https://doi.org/10.1002/cncr.32645
Dudek, AZ, Liu, LC, Gupta, S, Logan, TF, Singer, EA, Joshi, M, Zakharia, YN, Lang, JM, Schwarz, JK, Al-Janadi, A & Alva, AS 2020, 'Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003', Journal of Clinical Oncology, vol. 38, no. 11, pp. 1138-1145. https://doi.org/10.1200/JCO.19.02394
Yin, M, Grivas, P, Wang, QE, Mortazavi, A, Emamekhoo, H, Holder, SL, Drabick, JJ, Woo, MSA, Pal, S, Vasekar, M, Folefac, E, Clinton, SK, Monk, P & Joshi, M 2020, 'Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer', Oncologist, vol. 25, no. 8, pp. 680-688. https://doi.org/10.1634/theoncologist.2019-0851

2019

Voss, MH, Bhatt, RS, Vogelzang, NJ, Fishman, M, Alter, RS, Rini, BI, Beck, JT, Joshi, M, Hauke, R, Atkins, MB, Burgess, E, Logan, TF, Shaffer, D, Parikh, R, Moazzam, N, Zhang, X, Glasser, C, Sherman, ML & Plimack, ER 2019, 'A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma', Cancer, vol. 125, no. 14, pp. 2400-2408. https://doi.org/10.1002/cncr.32061
Joshi, A, Hillwig-Garcia, J, Joshi, M, Lehman, E, Khan, A, Llorente, A & Haidet, P 2019, 'Comics as an Educational Tool on a Clinical Clerkship', Academic Psychiatry, vol. 43, no. 3, pp. 290-293. https://doi.org/10.1007/s40596-018-1016-1
Yin, M, Zhao, J, Monk, P, Martin, D, Folefac, E, Joshi, M, Jin, N, Mortazavi, A, Verschraegen, C & Clinton, S 2020, 'Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in high-risk localized prostate cancer', Cancer medicine, vol. 9, no. 1, pp. 27-34. https://doi.org/10.1002/cam4.2605
Zhu, J, Hussain, M, Joshi, A, Truica, CI, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, JJ & Joshi, M 2020, 'Effect of creative writing on mood in patients with cancer', BMJ Supportive and Palliative Care, vol. 10, no. 1, pp. 64-67. https://doi.org/10.1136/bmjspcare-2018-001710
Loriot, Y, Necchi, A, Park, SH, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, ST, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A & Siefker-Radtke, AO 2019, 'Erdafitinib in locally advanced or metastatic urothelial carcinoma', New England Journal of Medicine, vol. 381, no. 4, pp. 338-348. https://doi.org/10.1056/NEJMoa1817323
Zaleski, M, Gogoj, A, Walter, V, Raman, JD, Kaag, M, Merrill, SB, Drabick, J, Joshi, M, Holder, S, DeGraff, DJ & Warrick, JI 2019, 'Mitotic activity in noninvasive papillary urothelial carcinoma: its value in predicting tumor recurrence and comparison with the contemporary 2-tier grading system', Human Pathology, vol. 84, pp. 275-282. https://doi.org/10.1016/j.humpath.2018.10.008
Joshi, M, Warrick, JI, Yin, M, Holder, SL & Drabick, JJ 2019, 'Need for a personalized approach for muscle invasive bladder cancer: Role of tumor biology in response to neoadjuvant chemotherapy', Translational Andrology and Urology, vol. 8, pp. S99-S103. https://doi.org/10.21037/tau.2018.12.04
Semrad, TJ, Groshen, S, Luo, C, Pal, S, Vaishampayan, U, Joshi, M, Quinn, DI, MacK, PC, Gandara, DR & Lara, PN 2019, 'Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor therapy in patients with renal cell carcinoma who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib-Results of NCI/CTEP protocol 9048', Kidney Cancer, vol. 3, no. 1, pp. 51-61. https://doi.org/10.3233/KCA-180041

2018

Yin, M, Grivas, P, Emamekhoo, H, Mendiratta, P, Ali, S, Hsu, JA, Vasekar, M, Drabick, JJ, Pal, S & Joshi, M 2018, 'ATM/RB1 mutations predict shorter overall survival in urothelial cancer', Oncotarget, vol. 9, no. 24, pp. 16891-16898. https://doi.org/10.18632/oncotarget.24738

2017

Venur, VA, Joshi, M, Nepple, KG & Zakharia, Y 2017, 'Spotlight on nivolumab in the treatment of renal cell carcinoma: Design, development, and place in therapy', Drug Design, Development and Therapy, vol. 11, pp. 1175-1182. https://doi.org/10.2147/DDDT.S110209

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)